

=> d his

(FILE 'HOME' ENTERED AT 18:28:32 ON 13 JUN 2004)

FILE 'MEDLINE, BIOSIS' ENTERED AT 18:28:48 ON 13 JUN 2004

|    |  |
|----|--|
| L1 | 0 S PRO7170  |
| L2 | 3446 S GLUCOSE (L) FATTY ACID? (L) UPTAKE                    |
| L3 | 17962 S (GLUCOSE OR FATTY ACID?) (W) UPTAKE                  |
| L4 | 468 S GLUCOSE (L) FATTY ACID? (L) UPTAKE (L) SKELETAL MUSCLE |
| L5 | 277 DUP REM L4 (191 DUPLICATES REMOVED)                      |
| L6 | 238 S L5 AND PY<2003   |
| L7 | 386 S (ASHKENAZI, A?)/AU                                     |
| L8 | 0 S L6 AND L7  |
| L9 | 0 S EXMAD  |

| L<br>Number | Hits | Search Text  | DB  | Time stamp          |
|-------------|------|--|---|---------------------|
| -           | 134  | PRO7170  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:16 |
| -           | 755  | bandman-o\$.in.  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:53 |
| -           | 4    | EXMAD  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:21 |
| -           | 3001 | glucose adj uptake   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:22 |
| -           | 391  | glucose with fatty adj acid with uptake                                  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:23 |
| -           | 4469 | (glucose fatty adj acid) with uptake                                     | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:22 |
| -           | 3039 | ((glucose fat\$ adj acid\$) with uptake)<br>and (fus\$ chimeric Ig flag) | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:24 |
| -           | 3    | EXMAD and (fus\$ chimeric Ig flag)                                       | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:25 |
| -           | 3    | EXMAD and (fus\$ chimeric immunoglobulin<br>flag heterol\$ tag his )     | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:26 |
| -           | 649  | ashkenazi-a\$.in.  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:49 |
| -           | 133  | PRO7170 and ashkenazi-a\$.in.  | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:49 |
| -           | 27   | (glucose with fatty adj acid with uptake)<br>and ashkenazi-a\$.in.       | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:53 |
| -           | 134  | PRO7170 and antibody   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:53 |
| -           | 4    | EXMAD and antibody   | USPAT;<br>US-PGPUB;<br>EPO; JPO;<br>DERWENT | 2004/06/08<br>17:53 |

XX PRO polynucleotides used to produce polypeptides used to target  
PT bioactive molecules such as toxins, radiolabels or antibodies, to  
PT specific cells, to cause targeted cell death -  
XX  
PS Claim 12; Fig 326; 935pp; English.  
XX  
CC The present invention describes human secreted and transmembrane PRO  
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins  
CC can be used for targeted delivery of bioactive molecules, such as  
CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide  
CC sequences, and their fragments, can be used as hybridisation probes, in  
CC chromosomal and gene mapping, and in the generation of anti-sense RNA  
CC and DNA. They may also be used to produce transgenic animals which are  
CC used to develop and screen therapeutically useful reagents. The PRO  
CC nucleotide and protein sequence can be used for tissue typing and in  
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.  
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used  
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and  
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein  
CC sequences given in the exemplification of the present invention.  
XX  
SQ Sequence 482 AA;

Query Match 100.0%; Score 2429; DB 22; Length 482;  
Best Local Similarity 100.0%; Pred. No. 1e-148;  
Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRADTAMTTDDTEVPAMTAPGHALETQTL 60  
Db 1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRADTAMTTDDTEVPAMTAPGHALETQTL 60  
QY 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFMVLIATSVETSAAGSPE 120  
Db 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFMVLIATSVETSAAGSPE 120  
QY 121 GAGMTTVQITGSDPEEAIFDITLCTDDSSBEAKTLTMDILTALHTSTEAKGLSSESSASS 180  
Db 121 GAGMTTVQITGSDPEEAIFDITLCTDDSSBEAKTLTMDILTALHTSTEAKGLSSESSASS 180  
QY 181 DGHPHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHP 240  
Db 181 DGHPHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHP 240  
QY 241 ALVTVTNIEVINCISITEIETTSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300  
Db 241 ALVTVTNIEVINCISITEIETTSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300  
QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLTSGALVTVSRNPLE 360  
Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLTSGALVTVSRNPLE 360  
QY 361 ETSALSVETPSYKVGSAAPVSI EAGSAVGKTTSFAGSSASSYSPSEAAALKNFTPSETPT 420  
Db 361 ETSALSVETPSYKVGSAAPVSI EAGSAVGKTTSFAGSSASSYSPSEAAALKNFTPSETPT 420  
QY 421 MDIATKGPFPSTRDPLPSVPPTTNSRGNTSLAKITTSAKTTMKPQQRPRPLPGRGRP 480  
Db 421 MDIATKGPFPSTRDPLPSVPPTTNSRGNTSLAKITTSAKTTMKPQQRPRPLPGRGRP 480  
QY 481 QT 482  
Db 481 QT 482

RESULT 4  
AAB27225  
ID AAB27225 standard; Protein; 482 AA.  
XX  
AC AAB27225;  
XX  
DT 27-MAR-2001 (first entry)  
XX

DE Human EXMAD-3 SEQ ID NO: 3.  
XX  
KW Extracellular matrix and adhesion-associated protein; EXMAD; cancer;  
KW inflammation; reproductive disorder; cardiovascular disorder;  
KW immune disorder; musculoskeletal disorder; developmental disorder;  
KW gastrointestinal disorder; cell proliferation disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO2000068380-A2.  
XX  
PD 16-NOV-2000.  
XX  
PF 10-MAY-2000; 2000WO-US12811.  
XX  
PR 11-MAY-1999; 99US-0133643.  
PR 23-AUG-1999; 99US-0150409.  
XX  
PA (INCY-) INCYTE GENOMICS INC.  
XX  
PI Bandman O, Hillman JL, Tang YT, Lal P, Yue H, Baughn MR, Lu DAM;  
PI Azimzai Y;  
XX  
DR WPI; 2001-007395/01.  
DR N-PSDB; AAC66892.  
XX  
PT Isolated polynucleotide encoding extracellular matrix or  
PT adhesion-associated protein (EXMAD) useful for diagnosing, treating, or  
PT preventing disorders associated with expression of EXMAD such as  
PT proliferative, immune and genetic disorders -  
XX  
PS Claim 1; Page 89-90; 129pp; English.  
XX  
CC The present invention provides the protein and coding sequences for 25  
CC novel extracellular matrix and adhesion-associated proteins (EXMADs).  
CC These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,  
CC EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,  
CC EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,  
CC EXMAD-20, EXMAD-21, EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are  
CC useful in the prevention and treatment of cancers, cell proliferation,  
CC cardiovascular, reproductive, immune, musculoskeletal, developmental and  
CC gastrointestinal disorders and inflammation.

Sequence 482 AA;  
Query Match 100.0%; Score 2429; DB 22; Length 482;  
Best Local Similarity 100.0%; Pred. No. 1e-148;  
Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRADTAMTTDDTEVPAMTAPGHALETQTL 60  
Db 1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRADTAMTTDDTEVPAMTAPGHALETQTL 60  
QY 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFMVLIATSVETSAAGSPE 120  
Db 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFMVLIATSVETSAAGSPE 120  
QY 121 GAGMTTVQITGSDPEEAIFDITLCTDDSSBEAKTLTMDILTALHTSTEAKGLSSESSASS 180  
Db 121 GAGMTTVQITGSDPEEAIFDITLCTDDSSBEAKTLTMDILTALHTSTEAKGLSSESSASS 180  
QY 181 DGHPHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHP 240  
Db 181 DGHPHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHPVITPSRAESSASSDGGHP 240  
QY 241 ALVTVTNIEVINCISITEIETTSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300  
Db 241 ALVTVTNIEVINCISITEIETTSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300  
QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLTSGALVTVSRNPLE 360  
Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLTSGALVTVSRNPLE 360

Tue Jan

QY 361 ETSALSVETPSYKVGSAAPVSI EAGSAVGKTTSFAGSSASSYSPSEALKNFTPSETPT 420  
D5 361 ETSALSVETPSYKVGSAAPVSI EAGSAVGKTTSFAGSSASSYSPSEALKNFTPSETPT 420  
QY 421 MDIATKGPFFTSRDPLPSVPPTTNSRGTNSILAKITTSAKTTMKPQPRPLPGRGRP 480  
D5 421 MDIATKGPFFTSRDPLPSVPPTTNSRGTNSILAKITTSAKTTMKPQPRPLPGRGRP 480  
QY 481 QT 482  
D5 481 QT 482  
RESULT 5  
ABU72052  
ID ABU72052 standard; Protein; 482 AA.  
XX  
AC ABU72052;  
XX  
DT 11-JUN-2003 (first entry)  
DE Novel human secreted and transmembrane protein PRO7170.  
XX  
KW Human; secreted and transmembrane polypeptide; PRO;  
KW fibroblast growth factor receptor; PRO533; PRO301; PRO187; PRO337;  
KW PRO1411; PRO10096; PRO246; PRO6307; PRO6003; FGFR-3; FGFR-4; FGFR-1;  
KW FGFR-2; PRO6004; PRO4356; PRO2630; PRO265; PRO951; bioactive molecule;  
KW toxin; radiolabel; antibody; cell death; chromosome mapping;  
KW gene mapping; transgenic animal; knockout animal; gene therapy;  
KW tissue typing.  
XX  
OS Homo sapiens.  
XX  
PN US2002177165-A1.  
XX  
PD 28-NOV-2002.  
XX  
PF 01-FEB-2002; 2002US-0066500.  
XX  
PR 14-JUL-1998; 98WO-US14552.  
PR 10-SEP-1998; 98WO-US18824.  
PR 14-SEP-1998; 98WO-US19093.  
PR 16-SEP-1998; 98WO-US19330.  
PR 17-SEP-1998; 98WO-US19437.  
PR 20-NOV-1998; 98WO-US24855.  
PR 25-NOV-1998; 98WO-US25190.  
PR 01-DEC-1998; 98WO-US25108.  
PR 08-MAR-1999; 99WO-US05028.  
PR 02-JUN-1999; 99WO-US12252.  
PR 01-SEP-1999; 99WO-US20111.  
PR 08-SEP-1999; 99WO-US20594.  
PR 15-SEP-1999; 99WO-US21090.  
PR 15-SEP-1999; 99WO-US21547.  
PR 30-NOV-1999; 99WO-US28313.  
PR 01-DEC-1999; 99WO-US28301.  
PR 02-DEC-1999; 99WO-US28565.  
PR 20-DEC-1999; 99WO-US30999.  
PR 05-JAN-2000; 2000WO-US00219.  
PR 18-FEB-2000; 2000WO-US04341.  
PR 18-FEB-2000; 2000WO-US04342.  
PR 22-FEB-2000; 2000WO-US04414.  
PR 01-MAR-2000; 2000WO-US05601.  
PR 02-MAR-2000; 2000WO-US05841.  
PR 09-MAR-2000; 2000WO-US06471.  
PR 20-MAR-2000; 2000WO-US07377.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 15-MAY-2000; 2000WO-US13358.  
PR 17-MAY-2000; 2000WO-US13705.  
PR 22-MAY-2000; 2000WO-US14042.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 11-AUG-2000; 2000WO-US22031.  
PR 23-AUG-2000; 2000WO-US23522.

PR 24-AUG-2000; 2000WO-US23328.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 28-FEB-2001; 2001WO-US06520.  
PR 30-MAY-2001; 2001WO-US17443.  
PR 01-JUN-2001; 2001WO-US17800.  
PR 20-JUN-2001; 2001WO-US19692.  
PR 29-JUN-2001; 2001WO-US21066.  
PR 09-JUL-2001; 2001WO-US21735.  
PR 26-AUG-1997; 97US-056974P.  
PR 17-SEP-1997; 97US-059115P.  
PR 18-SEP-1997; 97US-059263P.  
PR 19-SEP-1997; 97US-059588P.  
PR 17-OCT-1997; 97US-062285P.  
PR 24-OCT-1997; 97US-062816P.  
PR 24-OCT-1997; 97US-063082P.  
PR 27-OCT-1997; 97US-063329P.  
PR 29-OCT-1997; 97US-063733P.  
PR 21-NOV-1997; 97US-066364P.  
PR 25-NOV-1997; 97US-066840P.  
PR 16-DEC-1997; 97US-069694P.  
PR 09-FEB-1998; 98US-074086P.  
PR 09-FEB-1998; 98US-074092P.  
PR 25-MAR-1998; 98US-079294P.  
PR 08-APR-1998; 98US-081049P.  
PR 10-AUG-1998; 98US-095998P.  
PR 18-AUG-1998; 98US-097000P.  
PR 09-SEP-1998; 98US-099601P.  
PR 10-SEP-1998; 98US-099803P.  
PR 10-SEP-1998; 98US-099811P.  
PR 10-SEP-1998; 98US-099812P.  
PR 17-SEP-1998; 98US-100858P.  
PR 24-SEP-1998; 98US-101922P.  
PR 28-OCT-1998; 98US-106032P.  
PR 20-NOV-1998; 98US-109304P.  
PR 23-MAR-1999; 99US-125778P.  
PR 15-JUN-1999; 99US-139695P.  
PR 20-JUL-1999; 99US-145070P.  
PR 26-JUL-1999; 99US-145698P.  
PR 17-AUG-1999; 99US-149396P.  
PR 07-DEC-1999; 99US-169495P.  
PR 15-NOV-2001; 2001US-0002796.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Gurney AL, Kijavini IJ, Mather JP, Napier MA, Pan J;  
PI Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;  
PI Wood WI, Zhang Z;  
XX  
DR WPI; 2003-328482/31.  
DR N-PSDB; ACA60494.  
XX  
PT Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, for identifying agonists  
PT or antagonists of polypeptide, and as molecular weight markers -  
XX  
PS Claim 12; Fig 34; 254pp; English.  
XX  
CC The invention describes an isolated, secreted and transmembrane  
CC polypeptide (PP), termed PRO PP or fibroblast growth factor receptor PP  
CC (I). (I) is useful for detecting PRO533, PRO301, PRO187, PRO337,  
CC PRO1411, PRO10096, PRO246, PRO6307, PRO6003, fibroblast growth factor  
CC receptor (FGFR)-3, FGFR-4, FGFR-1, FGFR-2, PRO6004, PRO4356, PRO2630,  
CC PRO265 or PRO951 polypeptide, and for linking a bioactive molecule to a  
CC cell expressing the above polypeptides. The bioactive molecule, a toxin,  
CC radiolabel or an antibody, causes cell death. PRO is useful in assays to  
CC identify other proteins or molecules involved in binding interaction.  
CC The polynucleotide (II) encoding (I) is useful in chromosome and gene  
CC mapping, in generation of antisense RNA and DNA, for generating  
CC transgenic animals or knockout animals which in turn are useful in the  
CC development and screening of therapeutically useful reagents, to  
CC construct hybridisation probes for mapping the gene which encodes the